News
Deutsche Bank analysts downgraded Intuitive Surgical stock (NASDAQ: NASDAQ: ISRG) from a Hold to a Sell rating. The analysts also adjusted the price target to $440 from the previous $515, placing it ...
Zacks Investment Research on MSN6d
Intuitive Surgical Stock Gains 12.7% QTD: Is it Still a Buy Now?Shares of Intuitive Surgical ISRG seem to gain momentum after declining between February to April. The stock has risen 12.7% ...
US biotech Excision BioTherapeutics has raised $60 million to test a potential HIV cure in the clinic, which would use CRISPR technology to snip out the viral code from human cells and tissues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback